راهن٠ای جا٠ع تشخیص و در٠ان دیابت - دانشگاه علو٠پزشکی اردبیل

راهنماي جامع تشخیص و درمان دیابت15647. Pyorala K, Pedersen TR, Kjeksus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering withsimvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of theScandinavian Simvastatin Study (4S). Diabetes Care 20:614 –620, 199748. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM,Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effectof pravastatin on coronary events after myocardial infarction I patients with average cholesterol levels:Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335:1001– 1009, 199649. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention ofcardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range ofinitial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) StudyGroup. N Engl J Med 339:1349– 1357, 199850. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W,Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with averagecholesterol levels: results of AFCAPS/TexCAPS: Air Force/ Texas Coronary Atherosclerosis PreventionStudy. JAMA 279:1615–1622, 199851. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P,Manninen V: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middleaged men withdyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl JMed 317:1237–1245, 198752. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ,Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in menwith low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density LipoproteinCholesterol Intervention Trial Study Group. N Engl J Med 341:410–418, 199953. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of HighBlood Cholesterol in Adults(Adult Treatment Panel III): Executive summary of the third report of the NationalCholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation and Treatment of High BloodCholesterol in Adults(Adult Treatment Panel III). JAMA 285:2486–2497, 200154. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA:Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheralarterial disease. JAMA 284: 1263–1270, 200055. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS,Buse JB, Robertson DD, Sheehan JP: Efficacy, safety, and tolerability of once-daily niacin for the treatment ofdyslipidemia associated with type 2 diabetes. Arch Intern Med 162:1568–1576, 200256. Expert Panel on Blood Cholesterol Levels in Children and Adolescents: Treatment recommendations of theNational Cholesterol Education Program Report of the Expert Panel on Blood Cholesterol Levels in Children andAdolescents. Pediatrics 89 (Suppl.):525–584, 199257. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Amplified benefit of clopidogrel versusaspirin in patientrs with diabetes mellitus. Am J Cardiol 90:625–628, 200258. US Preventive Services Task Force: Counseling to prevent tobacco use. In Guide to Clinical PreventiveServices. 2 nd ed. Baltimore, MD, Williams & Wilkins, 1996, p. 597–60959. Fiore M, Bailey W, Cohen S: Smoking Cessation: Clinical Practice Guideline Number 18. Rockville, MD, USDepartment of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 199660. Garg J, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk fac-tor for cardiovascular disease.J Vasc Med 7:35–43, 200261. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH: Risk factors for development of incipient and overtdiabetic ne-phropathy in patients with non-insulin dependent diabetes mellitus: prospective, observationalstudy. BMJ 314:783–788, 199762. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-convertingenzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med156:286–289, 199663. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on thedevelopment of microvascular complications of diabetes mellitus. N Engl J Med 329:304–309, 199364. The DCCT Research Group: Effect of intensive therapy on the development and progression of diabeticnephropathy in the Diabetes Control and Complications Trial (DCCT). Kidney Int 47:1703–1720, 199565. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect ofangiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–1462, 1993